JP2015522000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522000A5 JP2015522000A5 JP2015519375A JP2015519375A JP2015522000A5 JP 2015522000 A5 JP2015522000 A5 JP 2015522000A5 JP 2015519375 A JP2015519375 A JP 2015519375A JP 2015519375 A JP2015519375 A JP 2015519375A JP 2015522000 A5 JP2015522000 A5 JP 2015522000A5
- Authority
- JP
- Japan
- Prior art keywords
- ace
- ophthalmic
- inhibitor
- converting enzyme
- angiotensin converting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 19
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 claims 9
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical group C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 8
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 8
- 108010061435 Enalapril Proteins 0.000 claims 8
- 108010007859 Lisinopril Proteins 0.000 claims 8
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims 8
- 229960000830 captopril Drugs 0.000 claims 8
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 8
- 229960000873 enalapril Drugs 0.000 claims 8
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 8
- 229960002490 fosinopril Drugs 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 229960002394 lisinopril Drugs 0.000 claims 8
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 8
- 229960005170 moexipril Drugs 0.000 claims 8
- 229960002582 perindopril Drugs 0.000 claims 8
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 8
- 229960001455 quinapril Drugs 0.000 claims 8
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 8
- 229960003401 ramipril Drugs 0.000 claims 8
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 8
- 229960004530 benazepril Drugs 0.000 claims 7
- 229960002051 trandolapril Drugs 0.000 claims 7
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 claims 4
- 229960002680 enalaprilat Drugs 0.000 claims 4
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims 4
- 239000003889 eye drop Substances 0.000 claims 4
- 229940012356 eye drops Drugs 0.000 claims 4
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 229940023490 ophthalmic product Drugs 0.000 claims 4
- ODAIHABQVKJNIY-PEDHHIEDSA-N perindoprilat Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@H]21 ODAIHABQVKJNIY-PEDHHIEDSA-N 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 230000004382 visual function Effects 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 3
- -1 moexiprilate Chemical compound 0.000 claims 3
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 claims 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 239000004090 neuroprotective agent Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- AHYHTSYNOHNUSH-HXFGRODQSA-N trandolaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 AHYHTSYNOHNUSH-HXFGRODQSA-N 0.000 claims 2
- 230000004304 visual acuity Effects 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 108010066671 Enalaprilat Proteins 0.000 claims 1
- 229960004067 benazeprilat Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960002231 ramiprilat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TN20120343 | 2012-06-29 | ||
| TNTN2012/0343 | 2012-06-29 | ||
| PCT/IB2013/001375 WO2014001889A1 (en) | 2012-06-29 | 2013-06-28 | Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522000A JP2015522000A (ja) | 2015-08-03 |
| JP2015522000A5 true JP2015522000A5 (enExample) | 2016-08-12 |
| JP6238977B2 JP6238977B2 (ja) | 2017-11-29 |
Family
ID=52471712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519375A Expired - Fee Related JP6238977B2 (ja) | 2012-06-29 | 2013-06-28 | 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9730949B2 (enExample) |
| EP (1) | EP2866805A1 (enExample) |
| JP (1) | JP6238977B2 (enExample) |
| CA (1) | CA2877590A1 (enExample) |
| RU (1) | RU2658461C2 (enExample) |
| WO (1) | WO2014001889A1 (enExample) |
| ZA (1) | ZA201500103B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108452309B (zh) * | 2018-03-05 | 2019-08-23 | 佳木斯大学附属第一医院 | 一种用于预防或治疗视神经炎的药物组合物及其制备方法 |
| RU2704013C1 (ru) * | 2019-04-18 | 2019-10-23 | ФГБНУ "НИИ глазных болезней" | Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656188A (en) | 1985-10-09 | 1987-04-07 | Merck & Co., Inc. | Ace inhibitors in macular degeneration |
| BR0011714A (pt) | 1999-06-16 | 2002-03-05 | Elyes Ben Mohamed Raouf Rekik | Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento |
| FR2826276A1 (fr) * | 2001-06-20 | 2002-12-27 | Raouf Rekik | Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie |
| RU2281023C2 (ru) * | 2004-10-26 | 2006-08-10 | Наталия Ивановна Курышева | Способ прогнозирования течения глаукоматозной оптической нейропатии |
| WO2010126911A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
-
2013
- 2013-06-28 RU RU2014152906A patent/RU2658461C2/ru not_active IP Right Cessation
- 2013-06-28 CA CA2877590A patent/CA2877590A1/en not_active Abandoned
- 2013-06-28 WO PCT/IB2013/001375 patent/WO2014001889A1/en not_active Ceased
- 2013-06-28 JP JP2015519375A patent/JP6238977B2/ja not_active Expired - Fee Related
- 2013-06-28 US US14/411,641 patent/US9730949B2/en not_active Expired - Fee Related
- 2013-06-28 EP EP13742737.3A patent/EP2866805A1/en not_active Withdrawn
-
2015
- 2015-01-07 ZA ZA2015/00103A patent/ZA201500103B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| RU2015122256A (ru) | Композиции, содержащие вортиоксетин и донепезил | |
| EA201291247A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2015522000A5 (enExample) | ||
| MX2021000349A (es) | Administracion de un inhibidor de la enzima activadora de sumo y anticuerpos anti-cd20. | |
| IN2015DN01738A (enExample) | ||
| PH12020500532A1 (en) | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin | |
| JP2014530246A5 (enExample) | ||
| MX2021010176A (es) | Inhibidor de enzimas activadoras de sumo e inhibidores de punto de control. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| Sahin et al. | Does the intrathecal propofol have a neuroprotective effect on spinal cord ischemia? | |
| NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
| RU2014152906A (ru) | Ингибиторы ангиотензинпревращающего фермента для лечения нейропатии зрительного нерва или врождённой атрофии зрительного нерва | |
| CN115397416A (zh) | 包含仑伐替尼的分子水平的药物组合物及其制备方法和应用 | |
| UA115333C2 (uk) | Склад есмололу для парентерального введення | |
| RU2011134582A (ru) | Ингибирующее дипептидилпептидазу iv средство и фармацевтическая композиция на его основе | |
| van der Does et al. | Comparison of the antihypertensive effect of imidapril and enalapril in the treatment of mild to moderate essential hypertension: a randomized, double-blind, parallel-group study | |
| Jacobson | AIM-HIGH: Niacin Provides No Added Benefit for Statin Users With Well-Controlled LDL. | |
| MX2020002312A (es) | Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina. |